CClinicalTrials.gg
Status unknownNCT05507086Blue sweatUpdated Aug 23, 2022

Infectious Pseudochromdrosis Caused by Bacillus Cereus

An observational study in Infectious Disease, Bacterial Overgrowth and Pigment Deposition, sponsored by Oslo University Hospital. Status unknown at 1 site in Norway. Per ClinicalTrials.gov, last updated 2022-08-23.

Sponsored by Oslo University Hospital · Observational

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
12
Sex
All
01

Study summary

Twelve patients with blue sweat (infectious pseudochromhidrosis) caused by Bacillus cereus.

Read the detailed description

Case series/observational study. Twelve patients with blue sweat (infectious pseudochromhidrosis) caused by Bacillus cereus. Demography, clinical presentation, diagnosis, treatments, microbiology and causality.

02

Conditions studied

  • Infectious Disease
  • Bacterial Overgrowth
  • Pigment Deposition

Keywords

  • Infectious pseudochromhidrosis
  • Chromhidrosis
  • Sweat
  • Bacillus cereus
03

In context

Communicable Diseases

4,451 studies on the registry are indexed under Communicable Diseases; 521 are open to participants now.

This study's planned enrollment of 12 is below the median of 244 across 1,499 observational studies indexed under Communicable Diseases.

Browse Communicable Diseases studies →

Lead sponsor

Oslo University Hospital is the lead sponsor of 810 studies on the registry; 148 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Twelve patients with blue sweat (infectious pseudochromhidrosis) caused by Bacillus cereus

Inclusion criteria

  • Infectious pseudochromhidrosis caused by Bacillus cereus

Exclusion criteria

Exclusion Criteria:

  • Other types of blue chromhidrosis
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
12 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • OtherAntimicrobial therapy

    Antimicrobial therapy

06

What researchers measure

Primary outcomes

  1. Remission

    Descriptive / physical examination

    Time frame: 1 year

  2. Repeated bacteriological swab

    Repeated bacteriological swab if uncertainty in terms of complete remission

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05507086
Lead sponsor
Oslo University Hospital
Responsible party
Christoffer Aam Ingvaldsen (Researcher, University Hospital, Akershus) — Principal investigator
First posted
Aug 18, 2022
Start date
Jan 1, 2020
Primary completion
Dec 31, 2022 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Aug 23, 2022

Study contacts

Christoffer A Ingvaldsen, MD PhD
Contact
aamingvaldsen@gmail.com
004741271030
Truls M Leegaard, MD PhD
Contact
truls.michael.leegaard@ahus.no

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion